Clinical Trial

Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer

Name: Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer — clinical trial record (NCT05525767)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This is an prospective, multicenter, single-arm clinical study.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2022-08-31.

Trial Details

NCT Number	NCT05525767
Lead Sponsor	Hebei Medical University Fourth Hospital
Conditions	Solid Tumor
Enrollment	75 participants
Start Date	2022-03-31
Primary Completion	2026-10-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-12-11